Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Presses FDA To Revise Combo Drug Exclusivity Policy For Duavee

Executive Summary

Citizen petition seeks five-year NCE exclusivity for Pfizer’s estrogen/bazedoxifene combo after district court tells FDA its inconsistent position is unreasonable.

You may also be interested in...



Ferring Wins In Combo Exclusivity Case; FDA Lacks 'Legitimate Reason' To Reject

Court finds FDA erred in not giving the fixed-dose combo product Prepopik five years of market exclusivity since it had awarded the exclusivity to similarly situated single-entity drug products.

All Over But The Lawsuits? NCE Exclusivity For Fixed-Dose Combos Remains Prospective

FDA rejects requests by firms to make new policy retroactive; Gilead’s Harvoni and Eisai’s Akynzeo fixed combos, approved the day FDA issued its final guidance, granted exclusivity.

J&J COVID-19 Vaccine Pause Expected To Be Brief, But Subsequent Use May Be Restricted

CDC’s ACIP likely to discuss criteria needed to lift pause and whether to recommend that the vaccine not be used in specific groups. Former CBER official says FDA and CDC will look at reports for other adenovirus vector vaccines, including J&J’s Ebola vaccine, and the biological plausibility that cases of rare blood clots are directly associated with the vaccine.

Topics

Related Companies

UsernamePublicRestriction

Register

PS119272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel